We are live on
!
Find out more
BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Est. Return
64.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.6%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$152M
AUM Growth
-$4.07M
(-2.6%)
Cap. Flow
-$12.2M
Cap. Flow
% of AUM
-8.03%
Top 10 Holdings %
Top 10 Hldgs %
76.82%
Holding
24
New
8
Increased
2
Reduced
4
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$12.5M |
| 2 |
Molina Healthcare
MOH
|
+$11M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$10.8M |
| 4 |
Biogen
BIIB
|
+$10.5M |
| 5 |
Boston Scientific
BSX
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cooper Companies
COO
|
+$14.3M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$12.9M |
| 3 |
Integra LifeSciences
IART
|
+$12.1M |
| 4 |
QGENF
QIAGEN NV
QGENF
|
+$10.6M |
| 5 |
STJ
St Jude Medical
STJ
|
+$10.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.95% |
| 2 | Consumer Staples | 8.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$17.7B
| $13.9M | 9.12% |
305,630
-50,880
| -14% | -$2.34M |
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $13.3M | 8.72% |
+328,430
| New | +$12.5M |
|
|
MJN
3
DELISTED
Mead Johnson Nutrition Company
MJN
| $12.3M | 8.05% |
135,045
-31,325
| -19% | -$2.65M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.5B
| $11.8M | 7.78% |
152,253
+77,253
| +103% | +$6.57M |
|
|
MASI
5
DELISTED
Masimo
MASI
| $11.5M | 7.55% |
218,960
+65,404
| +43% | +$3.08M |
|
|
ABMD
6
DELISTED
Abiomed Inc
ABMD
| $11.5M | 7.53% |
104,920
-18,670
| -15% | -$1.86M |
|
|
7
Boston Scientific
BSX
$65.8B
| $11M | 7.21% |
+469,900
| New | +$10.2M |
|
|
8
Vertex Pharmaceuticals
VRTX
$121B
| $10.8M | 7.09% |
+125,450
| New | +$10.8M |
|
9
Ironwood Pharmaceuticals
IRWD
$611M
| $10.7M | 7.05% |
+980,358
| New | +$9.58M |
|
|
10
Molina Healthcare
MOH
$10.3B
| $10.2M | 6.73% |
+205,270
| New | +$11M |
|
|
11
Biogen
BIIB
$29.9B
| $9.67M | 6.35% |
+40,000
| New | +$10.5M |
|
|
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
| $9.54M | 6.26% |
+159,660
| New | +$8.63M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $8.54M | 5.61% |
+36,940
| New | +$8.52M |
|
|
SHPG
14
DELISTED
Shire pic
SHPG
| $7.56M | 4.96% |
41,060
-4,090
| -9% | -$738K |
|
15
Agilent Technologies
A
$39.1B
| – | – |
-250,000
| Closed | -$9.96M |
|
|
16
Cooper Companies
COO
$13.7B
| – | – |
-370,760
| Closed | -$14.3M |
|
17
Quest Diagnostics
DGX
$25.1B
| – | – |
-92,949
| Closed | -$6.64M |
|
|
18
Integra LifeSciences
IART
$1.54B
| – | – |
-360,000
| Closed | -$12.1M |
|
19
Incyte
INCY
$23.5B
| – | – |
-85,000
| Closed | -$6.16M |
|
|
20
Ionis Pharmaceuticals
IONS
$9.35B
| – | – |
-318,490
| Closed | -$12.9M |
|
|
PDCO
21
DELISTED
Patterson Companies, Inc.
PDCO
| – | – |
-142,600
| Closed | -$6.63M |
|
|
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-45,000
| Closed | -$6.26M |
|
|
STJ
23
DELISTED
St Jude Medical
STJ
| – | – |
-190,140
| Closed | -$10.5M |
|
|
QGENF
24
DELISTED
QIAGEN NV
QGENF
| – | – |
-475,000
| Closed | -$10.6M |
|
Similar funds
BCM
RJA
RP
ACPVT
SFA
KL
KFS
FHC
Blue Jay Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Blue Jay Capital Management held 24 positions worth $152M, down 2.6% from $156M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Blue Jay Capital Management withdrew a net $12.2M in Q2 2016, closing 10 positions and reducing 4 holdings. Its most notable exit was Cooper Companies, an estimated $14.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 84% a quarter earlier, followed by Consumer Staples.
Against the trend, Blue Jay Capital Management opened a new position in Seagen Inc. Common Stock worth $13.3M.
- Blue Jay Capital Management's largest Q2 2016 buy was Seagen Inc. Common Stock: 328,430 shares worth $13.3M.
- Blue Jay Capital Management added most to BioMarin Pharmaceuticals in Q2 2016, an estimated $6.57M increase.
- Blue Jay Capital Management's biggest Q2 2016 reduction was Mead Johnson Nutrition Company, cutting an estimated $2.65M.
- Blue Jay Capital Management fully exited Cooper Companies in Q2 2016, selling an estimated $14.3M.
- Blue Jay Capital Management's ten largest holdings make up 77% of its $152M portfolio in Q2 2016.
- Blue Jay Capital Management opened 8 new positions and closed 10 in Q2 2016.
- Blue Jay Capital Management's portfolio value fell 2.6% quarter-over-quarter to $152M.
Based on Blue Jay Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.